# BC3 Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bc3-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Baltimore, US
- Website: www.bc3tech.com
- Total disclosed funding: $0.1M
- Latest round: Seed (Feb 1, 2018)
- Investors on record: 1

## About

BC3 Technologies develops innovative medical solutions that enhance emergency healthcare, particularly with products for managing life-threatening arterial bleeding.BC3 Technologies, founded in 2018 and headquartered in Baltimore, US, focuses on developing advanced medical solutions. The company was established to address urgent needs in emergency healthcare, particularly in hemostatic management. In February 2018, BC3 Technologies raised USD 0.15 mn in Seed funding led by Quake Capital Partners, which represented the total amount raised to date. The company has completed one deal.BC3 Technologies specializes in the development and provision of innovative medical solutions aimed at addressing critical needs in emergency healthcare, particularly in managing life-threatening arterial bleeding. Their flagship product, the SEAL Hemostatic Wound Spray, is designed to provide rapid hemostatic control in emergency situations, thereby enhancing patient outcomes during critical care. This product has been endorsed by Lieutenant General Ray Palumbo, US Army (retired), highlighting its credibility and efficacy in military and civilian applications. BC3 Technologies targets a diverse customer base that includes healthcare providers, emergency medical services, military organizations, and potentially disaster response units, with a focus on various geographical markets across the United States and potentially international markets where emergency medical care is paramount.BC3 Technologies operates under a transactional business model that focuses on direct sales to healthcare providers and emergency services organizations. The revenue is generated primarily through the sales of their SEAL Hemostatic Wound Spray, which is sold in bulk to institutions and organizations that require immediate access to advanced medical treatments. Additionally, partnerships may be formed with emergency service providers to ensure a steady supply of their products. The structure supports a B2B model, with transactions potentially negotiated based on volume and contract lengths tailored to the specific needs of clients. While precise pricing details are not disclosed, the model suggests a tiered pricing strategy that accommodates varying order sizes to meet the demands of different client segments.BC3 Technologies aims to expand its product line with new innovations in hemostatic solutions, although specific upcoming product launches and release dates were not detailed. The company plans to target expansion into new geographical regions, including international markets, to address the growing demand for emergency medical care. The recent Seed funding of USD 0.15 mn raised in February 2018 will be utilized to support these initiatives, enhancing their capacity to develop new products and broaden their market reach.

## Funding rounds

- Seed, Feb 1, 2018, $0.1M — Quake Capital Partners

## Investors

- Quake Capital Partners (https://capitalatlas.ai/funds/quake-capital-partners) — Seed